Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records

Table 6 Path analysis showing relationships between Dyanavel, end of dose crash, and IR supplementation at 90 days

Regression weights	Estimate	SE	CR	p
End of dose crash^a ← Dyanavel XR	− 0.35	0.11	-3.30	< 0.001
IR supplementation ← End of dose crash^a	0.01	0.01	1.22	0.22
IR supplementation^a ← Dyanavel XR	− 0.05	0.02	-2.03	0.04

CR, critical ratio; IR, immediate release; SE, standard error; XR, extended release
^a At the time of visit falling closest to 90 days after ER stimulant was prescribed

ISSN: 1471-244X